CBS 2019
CBSMD教育中心
中 文

动脉粥样硬化性心血管疾病预防

Abstract

Recommended Article

Assessment of Vascular Dysfunction in Patients Without Obstructive Coronary Artery Disease: Why, How, and When When, where, and how to target vascular inflammation in the post-CANTOS era? Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS) MINOCA: a heterogenous group of conditions associated with myocardial damage Hypertension: Do Inflammation and Immunity Hold the Key to Solving this Epidemic? CD163+ macrophages promote angiogenesis and vascular permeability accompanied by inflammation in atherosclerosis 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes Endocardium Minimally Contributes to Coronary Endothelium in the Embryonic Ventricular Free Walls

Original Research2021 Mar 25;cvab100.

JOURNAL:Cardiovasc Res. Article Link

Treatment and prevention of lipoprotein(a)-mediated cardiovascular disease: the emerging potential of RNA interference therapeutics

DI Swerdlow, DA Rider, A Yavari et al. Keywords: lipoprotein(a)-mediated cardiovascular disease; treatment option; RNA interference therapeutics

Full Text PDF